We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 136.50 | 133.00 | 140.00 | 136.50 | 136.50 | 136.50 | 10,969 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.51 | 41.8M |
TIDMAREC
RNS Number : 5055D
Arecor Therapeutics PLC
29 June 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Director Dealing
Cambridge, UK, 29(th) June 2021. Arecor Therapeutics plc (AIM: AREC) , the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Susan Lowther, Chief Financial Officer, has purchased 12,515 ordinary shares of GBP0.01 each in the capital of the Company ("Ordinary Shares") at a price of 235 pence per Ordinary Share.
Following the transaction, the total beneficial interest of Susan Lowther is 110,681 Ordinary Shares, representing 0.40% of the total voting rights.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060 Officer Email: info@arecor.com Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Mo Noonan, Communications Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500 and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) Consilium Strategic Communications Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700 Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat(TM) technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Susan Lowther ------------------------------- -------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------- a) Position/status Chief Financial Officer ------------------------------- -------------------------------------- b) Initial notification/Amendment Initial notification ------------------------------- -------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------- a) Name Arecor Therapeutics plc ------------------------------- -------------------------------------- b) LEI 98450093D12I3A8DDD58 ------------------------------- -------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------- a) Description of the Ordinary Shares financial instrument, type of instrument ------------------------------- -------------------------------------- b) Identification Code GB00BMWLM973 ------------------------------- -------------------------------------- c) Nature of the transaction Purchase of shares ------------------------------- -------------------------------------- d) Price(s) and volume(s) 235 pence and 12,515 Ordinary Shares ------------------------------- -------------------------------------- e) Aggregated information N/A - Aggregated volume - Aggregated price ------------------------------- -------------------------------------- f) Date of the transaction 29 June 2021 ------------------------------- -------------------------------------- g) Place of the transaction London Stock Exchange, AIM ------------------------------- --------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGZGZVMLFGMZM
(END) Dow Jones Newswires
June 29, 2021 07:05 ET (11:05 GMT)
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions